Table 3.
Patient number | Tissue source |
CT (mean)* |
SEM† |
CT (mean) |
SEM |
---|---|---|---|---|---|
B7-H1− tumors | |||||
1 | Lymph node metastasis | UD‡ | NA | 33.19 | 0.45 |
2 | Small bowel metastasis | UD§ | NA | 34.46 | 0.38 |
3 | Lymph node metastasis | UD | NA | 32.93 | 0.11 |
4 | Lymph node metastasis | UD | NA | 35.53 | 0.28 |
5 | Cutaneous primary lesion | UD | NA | 36.11 | 0.13 |
B7-H1+ tumors | |||||
6 | Lymph node metastasis | 34.67 | 0.49 | 32.41 | 0.16 |
7 | Lymph node metastasis | 35.00 | 0.32 | 33.55 | 0.36 |
8 | Lung metastasis | 33.15 | 0.30 | 31.91 | 0.78 |
9 | Lung metastasis | 31.80 | 0.07 | 28.43 | 0.02 |
10 | Lymph node metastasis | 35.17 | 0.22 | 32.51 | 0.22 |
Controls | |||||
NA | PBMCs | 33.12 | 0.35 | 28.55 | 0.66 |
NA | Activated CD3+ T cells | 23.60 | 0.08 | 28.33 | 0.11 |
NA | 1359-mel | UD | NA | UD | NA |
Lower values reflect greater expression.
SEM of triplicate samples.
One of three triplicate reactions for patient 1 tumor had CT = 41.7, and two of three were undetectable and average undetectable.
One of three triplicate reactions for patient 2 tumor had CT = 43.1, and two of three were undetectable and average undetectable.